Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics

Cheng,Ka-Wing; Wong,Chi  C.; Mattheolabakis,George; Xie,Gang; Huang,Liqun; Rigas,Basil

doi:10.3892/ijo.2013.1995

Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics

Authors:
- Ka-Wing Cheng
- Chi C. Wong
- George Mattheolabakis
- Gang Xie
- Liqun Huang
- Basil Rigas
View Affiliations

Affiliations: Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794-8173, USA
Published online on: June 27, 2013 https://doi.org/10.3892/ijo.2013.1995
Pages: 895-902

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phospho-sulindac (PS) is a safe sulindac derivative with promising anticancer efficacy in colon cancer. We evaluated whether its combination with curcumin could enhance the efficacy in the treatment of lung cancer. Curcumin, the principal bioactive component in turmeric, has demonstrated versatile capabilities to modify the therapeutic efficacy of a wide range of anticancer agents. Here, we evaluated the effect of co-administration of curcumin on the anticancer activity of PS in a mouse xenograft model of human lung cancer. Curcumin enhanced the cellular uptake of PS in human lung and colon cancer cell lines. To assess the potential synergism between curcumin and PS in vivo, curcumin was suspended in 10% Tween-80 or formulated in micellar nanoparticles and given to mice by oral gavage prior to the administration of PS. Both formulations of curcumin significantly improved the pharmacokinetic profiles of PS, with the 10% Tween-80 suspension being much more effective than the nanoparticle formation. However, curcumin did not exhibit any significant modification of the metabolite profile of PS. Furthermore, in a mouse subcutaneous xenograft model of human lung cancer, PS (200 mg/kg) in combination with curcumin (500 mg/kg) suspended in 10% Tween-80 (51% inhibition, p<0.05) was significantly more efficacious than PS plus micelle curcumin (30%) or PS (25%) or curcumin alone (no effect). Consistent with the improved pharmacokinetics, the combination treatment group had higher levels of PS and its metabolites in the xenografts compared to PS alone. Our results show that curcumin substantially improves the pharmacokinetics of PS leading to synergistic inhibition of the growth of human lung cancer xenografts, representing a promising drug combination.

View Figures

View References

1	Elwood PC, Gallagher AM, Duthie GG, Mur LA and Morgan G: Aspirin, salicylates and cancer. Lancet. 373:1301–1309. 2009. View Article : Google Scholar : PubMed/NCBI
2	Rothwell PM, Price JF, Fowkes FG, et al: Short-term effects of daily aspirin on cancer incidence, mortality and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 379:1602–1612. 2012. View Article : Google Scholar : PubMed/NCBI
3	Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
4	Cheng KW, Mattheolabakis G, Wong CC, et al: Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol. 41:1199–1203. 2012.PubMed/NCBI
5	Huang L, Mackenzie GG, Sun Y, et al: Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Res. 71:7617–7627. 2011. View Article : Google Scholar : PubMed/NCBI
6	Mackenzie GG, Ouyang N, Xie G, et al: Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res. 4:1052–1060. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhu C, Cheng KW, Ouyang N, et al: Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts. Stem Cells. 30:2065–2075. 2012. View Article : Google Scholar : PubMed/NCBI
8	Zhu R, Cheng KW, Mackenzie G, et al: Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles. Pharm Res. 29:3090–3101. 2012. View Article : Google Scholar : PubMed/NCBI
9	Hanif R, Qiao L, Shiff SJ and Rigas B: Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med. 130:576–584. 1997. View Article : Google Scholar : PubMed/NCBI
10	Kawamori T, Lubet R, Steele VE, et al: Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 59:597–601. 1999.PubMed/NCBI
11	Villegas I, Sanchez-Fidalgo S and de la Lastra CA: Chemopreventive effect of dietary curcumin on inflammation-induced colorectal carcinogenesis in mice. Mol Nutr Food Res. 55:259–267. 2011. View Article : Google Scholar : PubMed/NCBI
12	Su CC, Yang JS, Lu CC, et al: Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. Phytother Res. 24:189–192. 2010.PubMed/NCBI
13	Dance-Barnes ST, Kock ND, Moore JE, et al: Lung tumor promotion by curcumin. Carcinogenesis. 30:1016–1023. 2009. View Article : Google Scholar : PubMed/NCBI
14	Giladi N, Kazanov D, Shpitz B, Aroch I, Kraus S and Arber N: Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer. Expert Opin Investig Drugs. 19:S117–S124. 2010. View Article : Google Scholar : PubMed/NCBI
15	Lee JY, Lee YM, Chang GC, et al: Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PloS One. 6:e237562011. View Article : Google Scholar : PubMed/NCBI
16	Yin H, Guo R, Xu Y, et al: Synergistic antitumor efficiency of docetaxel and curcumin against lung cancer. Acta Biochim Biophys Sin. 44:147–153. 2012. View Article : Google Scholar : PubMed/NCBI
17	Ganta S and Amiji M: Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 6:928–939. 2009. View Article : Google Scholar : PubMed/NCBI
18	Sung B, Kunnumakkara AB, Sethi G, et al: Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther. 8:959–970. 2009. View Article : Google Scholar : PubMed/NCBI
19	Francois G and Katz JL: Nanoparticles and nanocapsules created using the Ouzo effect: spontaneous emulisification as an alternative to ultrasonic and high-shear devices. Chemphyschem. 6:209–216. 2005. View Article : Google Scholar : PubMed/NCBI
20	Galindo-Rodriguez S, Allemann E, Fessi H and Doelker E: Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion and nanoprecipitation methods. Pharm Res. 21:1428–1439. 2004. View Article : Google Scholar
21	Wong CC, Cheng KW, Xie G, et al: Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity. J Pharmacol Exp Ther. 340:422–432. 2012. View Article : Google Scholar : PubMed/NCBI
22	Balimane PV, Han YH and Chong S: Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 8:E1–E13. 2006. View Article : Google Scholar : PubMed/NCBI
23	Xie G, Nie T, Mackenzie GG, et al: The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol. 165:2152–2166. 2012. View Article : Google Scholar : PubMed/NCBI
24	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
25	Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV and Limtrakul P: Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II and III purified from Turmeric powder. Biochem Pharmacol. 68:2043–2052. 2004. View Article : Google Scholar : PubMed/NCBI
26	Shukla S, Zaher H, Hartz A, et al: Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 26:480–487. 2009. View Article : Google Scholar : PubMed/NCBI
27	Wortelboer HM, Usta M, van der Velde AE, et al: Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol. 16:1642–1651. 2003. View Article : Google Scholar : PubMed/NCBI
28	Wortelboer HM, Usta M, van Zanden JJ, et al: Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of alpha,beta-unsaturated carbonyl compounds. Biochem Pharmacol. 69:1879–1890. 2005. View Article : Google Scholar : PubMed/NCBI
29	Li Y, Revalde JL, Reid G and Paxton JW: Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol. 68:603–610. 2011. View Article : Google Scholar : PubMed/NCBI
30	Rigas B and Shiff SJ: Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenases and the cell cycle. Their interactions in colon cancer. Adv Exp Med Biol. 470:119–126. 1999. View Article : Google Scholar : PubMed/NCBI